08:00 , Feb 18, 2013 |  BC Week In Review  |  Clinical News

biOasis preclinical data

In mice inoculated with a HER2-overespressing human breast cancer cell line that migrated to the brain and established brain tumors, twice-weekly subcutaneous BT2111 significantly reduced the mean number of HER2+ breast cancer tumors in the...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Clinical News

biOasis preclinical data

In a mouse xenograft model of aggressive human breast carcinoma, twice-weekly subcutaneous BT2111 completely halted tumor growth vs. a 400% increase in tumor size for placebo (p=0.0058). BT2111 was also at least non-inferior to active...
07:00 , Jul 18, 2011 |  BC Week In Review  |  Clinical News

biOasis preclinical data

In HER2-positive breast cancer cell lines, BT2111 displayed significantly improved anticancer activity vs. trastuzumab alone. BT2111 is trastuzumab conjugated to biOasis' Transcend carrier protein. Transcend is a p97 carrier protein that transports therapeutics across...